Clinical efficacy of hydroquinone in glaucoma patients with prostaglandin-induced eyelid pigmentation

Clinical efficacy of hydroquinone in glaucoma patients with prostaglandin-induced eyelid pigmentation - Clinical efficacy of hydroquinone in prostaglandin-induced eyelid pigmentation

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011524

Enrollment

Registered

2013-08-26

Start date

2013-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostaglandin-induced eyelid pigmentation

Interventions

Hydroquinone (RXDH) is applied to either eyelid twice daily for 3 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)20 years or older when the informed consent was taken 2)Glaucoma was diagnosed in both eyes 3)Subjects treated for 3 months with prostaglandin analogues 4)Symmetry in the skin color of eyelid between right and left eyes 5)Patients who agreed and signed to the participation in this study 6)Patients who can observed the schedule written in trial implementation protocol

Exclusion criteria

Exclusion criteria: 1)Severe glaucoma(a Humphery field analyzer: MD <-18dB) 2)Subjects who do not continue taking prostaglandin analogues 3)Subjects who took the internal medicine containing tranexamic acid, L- cysteine or vitamin C in the past 2 months 4)Subjects who used the quasi drugs or the cosmetic products for whitening in the past 3 months 5)Subjects who underwent the plastic treatment (e.g. LASER, Photo facial, and chemical peeling) in the past 2 months 6)Subjects who are exposed to the severe ultraviolet rays 7)Subjects with severe systematic diseases(e.g. hepatic disease) 8)Females who are pregnant or breast feeding, and females of childbearing potential during trial periods 9)Subjects who were enrolled in other clinical trials in the past 1 month 10)Subjects who are considered ineligible by the principal or other investigators

Design outcomes

Primary

Measure	Time frame
Skin color change of eyelid	—

Secondary

Measure	Time frame
Patient self-assessment of change in eyelid color Frequency and severity of adverse effects	—

Countries

Japan

Contacts

Public ContactKoichi ONO

Juntendo Tokyo-Koto Geriatric Medical Center, Juntendo University School of Medicine Ophthalmology

kono@juntendo.ac.jp03-5632-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026